101 related articles for article (PubMed ID: 2786473)
1. The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment.
Carter KC; Gallagher G; Baillie AJ; Alexander J
Eur J Immunol; 1989 Apr; 19(4):779-82. PubMed ID: 2786473
[TBL] [Abstract][Full Text] [Related]
2. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis.
Liew FY; Millott S; Li Y; Lelchuk R; Chan WL; Ziltener H
Eur J Immunol; 1989 Jul; 19(7):1227-32. PubMed ID: 2503386
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB/c mice.
Solbach W; Forberg K; Kammerer E; Bogdan C; Röllinghoff M
J Immunol; 1986 Jul; 137(2):702-7. PubMed ID: 3487578
[TBL] [Abstract][Full Text] [Related]
4. L3T4+ T cells promoting susceptibility to murine cutaneous leishmaniasis express the surface marker Ly-24 (Pgp-1).
Moll H; Scollay R
Eur J Immunol; 1989 Feb; 19(2):307-14. PubMed ID: 2467816
[TBL] [Abstract][Full Text] [Related]
5. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
Belosevic M; Finbloom DS; Van Der Meide PH; Slayter MV; Nacy CA
J Immunol; 1989 Jul; 143(1):266-74. PubMed ID: 2499629
[TBL] [Abstract][Full Text] [Related]
6. Analysis of variables associated with promotion of resistance and its abrogation in T cell-reconstituted nude mice infected with Leishmania major.
Moll H; Mitchell GF
J Parasitol; 1988 Dec; 74(6):993-8. PubMed ID: 3264023
[TBL] [Abstract][Full Text] [Related]
7. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
Scott P; Pearce E; Natovitz P; Sher A
J Immunol; 1987 Jul; 139(1):221-7. PubMed ID: 3495599
[TBL] [Abstract][Full Text] [Related]
8. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
[TBL] [Abstract][Full Text] [Related]
9. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major.
Doherty TM; Coffman RL
J Immunol; 1993 Jun; 150(12):5476-83. PubMed ID: 8515072
[TBL] [Abstract][Full Text] [Related]
10. Immunization of susceptible hosts with a soluble antigen fraction from Leishmania major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells.
Bogdan C; Schröppel K; Lohoff M; Röllinghoff M; Solbach W
Eur J Immunol; 1990 Dec; 20(12):2533-40. PubMed ID: 1980108
[TBL] [Abstract][Full Text] [Related]
11. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
Liew FY; Dhaliwal JS
J Immunol; 1987 Jun; 138(12):4450-6. PubMed ID: 3295049
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major.
Behforouz NC; Wenger CD; Mathison BA
J Immunol; 1986 Apr; 136(8):3067-75. PubMed ID: 3958489
[TBL] [Abstract][Full Text] [Related]
13. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
[TBL] [Abstract][Full Text] [Related]
14. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro.
Sadick MD; Locksley RM; Tubbs C; Raff HV
J Immunol; 1986 Jan; 136(2):655-61. PubMed ID: 3079789
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secrete interferon-gamma and mediate parasite-specific delayed-type hypersensitivity.
Titus RG; Müller I; Kimsey P; Cerny A; Behin R; Zinkernagel RM; Louis JA
Eur J Immunol; 1991 Mar; 21(3):559-67. PubMed ID: 1672641
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
Liew FY; Howard JG; Hale C
J Immunol; 1984 Jan; 132(1):456-61. PubMed ID: 6228580
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of C.B-17 scid mice with BALB/c T cells initiates a T helper type-1 response and renders them capable of healing Leishmania major infection.
Varkila K; Chatelain R; Leal LM; Coffman RL
Eur J Immunol; 1993 Jan; 23(1):262-8. PubMed ID: 8419179
[TBL] [Abstract][Full Text] [Related]
18. [An immunologic method of producing antigens for the treatment and prevention of leishmaniasis].
Vouldoukis I; Monjour L
C R Acad Sci III; 1989; 308(5):129-34. PubMed ID: 2493318
[TBL] [Abstract][Full Text] [Related]
19. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed-type hypersensitivity.
Titus RG; Lima GC; Engers HD; Louis JA
J Immunol; 1984 Sep; 133(3):1594-600. PubMed ID: 6205088
[TBL] [Abstract][Full Text] [Related]
20. Higher frequency of Leishmania major-specific L3T4+ T cells in susceptible BALB/c as compared with resistant CBA mice.
Milon G; Titus RG; Cerottini JC; Marchal G; Louis JA
J Immunol; 1986 Feb; 136(4):1467-71. PubMed ID: 2418115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
